Acceleron's blood disorder drug candidate wins orphan status

03/27/2013 | Boston Herald

The FDA has given orphan-drug status to Acceleron Pharma's experimental beta-thalassemia and myelodysplastic syndrome treatment ACE-536. The red blood cell booster is being developed by Acceleron in partnership with Celgene.

View Full Article in:

Boston Herald

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX